ACLS Drugs and Doses    body {font-family: 'Open Sans', sans-serif;}

### ACLS Drugs and Doses

**Adenosine  
****Primary Uses:**

-   SVT/PSVT
-   Wide QRS tachycardia.

**Dose:**

-   _First Dose:_ 6 mg IV Push.
-   _Second Dose:_ 12 mg IV Push.

**Cautions/Notes:**

-   Must be given as a bolus, followed by a flush.
-   Can cause bronchospasm–use caution in asthmatics.
-   Flushing and chest tightness are common.

  
**Amiodarone  
****Primary Uses:**

-   Pulseless VT
-   Ventricular fibrillation (V-Fib)
-   Recurrent hemodynamically unstable ventricular tachycardia.
-   Hypertrophic cardiomyopathy.
-   Supraventricular tachyarrhythmias.

**Dose:**

-   _VT / V-Fib:_ 300 mg IV/IO. May give 150 mg after initial dose.
-   _Tachy / VT:_ 150 mg IV/IO over 10 minutes. Continuous infusion of 1 mg/min IV for 6 hours, 0.5 mg/min IV for next 18 hours.

**Cautions/Notes:**

-   Atrial fibrillation, hypertrophic cardiomyopathy and supraventricular arrhythmias are often treated with oral form of amiodarone.
-   Rapid infusion causes hypotension. 
-   If cumulative dosing exceeds 2.2 grams in 24 hours, significant hypotension can occur. Avoid administration with any drug that may prolong QT interval.

  
**Atropine  
****Primary Uses:**

-   Symptomatic bradycardia
-   Cardiac arrest

**Dose:**

-   0.5 mg IV (repeat every 3 – 5 minutes.
-   Max dose: 3 mg.

**Cautions/Notes:**

-   Dose less than 0.5 mg may cause paradoxical bradycardia.

  
**Dopamine  
****Primary Uses:**

-   Bradycardia
-   Hypotension

**Dose:**

-   2- 20 mcg/kg/min infusion.
-   Titrated based on clinical response; tapered on/off slowly.

**Cautions/Notes:**

-   Extravasation causes tissue damage and necrosis.
-   Use caution if giving high doses through peripheral IV site.
-   May cause excessive vasoconstriction / tachyarrhythmias.
-   Adequate volume resuscitation required before initiating dopamine therapy.

  
**Epinephrine  
****Primary Uses:**

-   Cardiac arrest
-   Symptomatic bradycardia
-   Anaphylaxis / severe allergic reactions
-   Severe hypotension

**Dose:**

-   1 mg (10 mL of 1:10,000 solution)
-   Repeat every 3 – 5 minutes
-   IV fluid flush following each dose.

**Cautions/Notes:**

-   Higher doses often needed in cases of beta-blocker or calcium channel blocker overdoses. A continuous
-   infusion may be required.
-   High dose does not improve survival / neurological outcome.
-   High dose ceases myocardial dysfunction in post-resuscitation period.

  
**Lidocaine  
****Primary Uses:**

-   Ventricular tachycardia
-   Ventricular fibrillation

**Dose:**

-   _Cardiac arrest from VT / VT:_ 1 – 1.5 mg/kg IV/IO
-   _Refractory VF:_ additional 0.5 – 0.75 mg/kg IV/IO; Repeat every 5 – 10 minutes for max of 3 doses, or 3 mg/kg
-   _Stable VT:_ 0.5 – 0.75 mg/kg up to 1.5 mg/kg; Repeat in 0.5 – 0.75 mg/kg doses to max of 3 mg/kg
-   _Maintenance infusion:_ 1 – 4 mg/min

**Cautions / Notes:**

-   _Not_ recommended routinely after cardiac arrest, but can be used following return of spontaneous circulation (ROSC).
-   Can also be used for stable polymorphic ventricular tachycardia with normal baseline QT AND torsades.
-   Decrease maintenance doses if left ventricular dysfunction or if impaired liver function.
-   Not used prophylactically after myocardial infarction.

  
**Magnesium  
****Primary Uses:**

-   Torsades de pointes
-   Hypomagnesemia (low magnesium)
-   Digitalis toxicity

**Dose:**

-   _Initial dose:_ 1 – 2 g IV/IO diluted in 10 mL D 5 W.
-   _Infusion dose:_ 0.5 – 1 g/hour.

**Cautions/Notes:**

-   Rapid administration may drop blood pressure.
-   Very high doses can cause respiratory distress (calcium is antidote).
-   Use with caution for patients with renal failure.

  
**Procainamide  
****Primary Uses:**

-   Ventricular arrhythmias
-   Supraventricular arrhythmias

**Dose:**

-   _Loading dose:_ 15 – 17 mg/kg IV. Give over _at least_ 30 minute
-   _Max: 1.5 grams_

**Cautions/Notes:**

-   Serious reactions can occur with prolonged use: including provocation of arrhythmias, asystole, seizures, decreased platelets, neutrophilia, hemolytic anemia, exacerbation of myasthenia gravis, and positive anti-nuclear antibody (ANA) test with or without signs of a lupus erythematosis-like syndrome.
-   Other common reactions include hypertension, bradycardia, angioedema, flushing, anaphylaxis (due to metabisulfite preservative), and urticaria.